search
Back to results

SIT LESS 2: Effect of Sitting Less on Glucose Regulation in People With Diabetes Mellitus Type 2 (SIT LESS 2)

Primary Purpose

Type 2 Diabetes

Status
Completed
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
Physical activity intervention
Sponsored by
Maastricht University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes focused on measuring Glucose regulation, Glucose, Lipids

Eligibility Criteria

40 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Signed informed consent
  • Men and women: 40-75 years old
  • Diabetes mellitus type 2, developed after the age of 40 years old
  • Treatment with diet or oral blood glucose lowering medication (metformin and/or SU-derivatives and/or DPP-IV inhibitors)
  • HbA1c: < 10%
  • BMI: 25.0 - 35.0 kg/m2
  • Maximum 2.5 hours of MVPA per week (during last 3 months)
  • Internet availability on a daily basis

Exclusion Criteria:

  • Pregnancy or intention of becoming pregnant
  • Alcohol use: > 2 units per day (during the last 3 months)
  • Experimental drug use (during the last 3 months)
  • Use of insulin, corticosteroids, vitamin K antagonists and immunosuppressive drugs in the last 3 months
  • Triglyceride level > 10.0 mmol/L
  • Fasting plasma glucose level > 10 mmol/L
  • Heart failure NYHA 3 or higher
  • Angina pectoris or signs of cardiac ischemia during exercise testing
  • COPD Gold 3 or higher
  • Glomerular filtration rate (GFR) < 30 ml/min
  • Diagnosis of active cancer (not cancer in the past that is cured)
  • Diabetes mellitus type 1
  • Intermittent claudication with a walking distance < 500 meter
  • Not able to cycle for ± 45 minutes, as judged from the incremental exhaustive exercise bicycle-ergometer test at Visit 1
  • Based on historical information not able to walk for 3 hours per day and stand for 4 hours per day
  • Mental or physical disability which makes physical activity not possible
  • Participation in a clinical trial with medication use (in the last 3 months)
  • Severe loss of vision
  • Active foot ulcer or venous leg ulcer

Sites / Locations

  • Human Movement Science, Maastricht University

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Sitting regime

Sit Less regime

Exercise regime

Arm Description

The subjects will follow the sitting regime during four days. Each day: 14 hours sitting, 1 hour walking and 1 hour standing for daily care and 8 hours sleeping or lying.

Subjects will follow the sit less regime during four days. Each day will consist of 3 hours walking, 4 hours standing, 9 hours sitting and 8 hours sleeping or lying. The additional 2 hours of walking and 3 hours of standing, compared to the sitting regime, will be done in a minimum of four bouts with a time interval of > 1 hour. The subjects will be instructed to walk on a slow pace. i.e. 2-3 km/h, which is comparable to walking during shopping, walking to the office etc.

Subjects will follow the exercise regime during four days. Each day will consist of 13 hours and 15 minutes sitting, ± 45 minutes supervised cycling on an ergometer, 1 hour walking and 1 hour standing for daily care and 8 hours sleeping or lying.

Outcomes

Primary Outcome Measures

Mean 24 hour glucose concentration

Secondary Outcome Measures

Total duration (minutes) of hyperglycaemia (glucose > 10 mmol/L)
Mean 24 hour glucose concentration
Total duration of hyperglycaemia (glucose > 10 mmol/L)
Area under the curve of hyperglycaemia (glucose > 10 mmol/L)
Glucose variability measured as SD divided by mean
Total duration of hypoglycaemia (glucose ≤ 3.9 mmol/L)
Fasting total cholesterol
Non-HDL cholesterol
HDL cholesterol
LDL cholesterol
Triglycerides
Apolipoprotein B
Apolipoprotein A
Free fatty acids
Fasting glucose
Fasting insulin
Fasting C-peptide
Fasting CRP
Fasting IL-6
Fasting IL-1
Homeostatic model assessment 2 (HOMA2)
to assess insulin sensitivity

Full Information

First Posted
January 22, 2015
Last Updated
March 15, 2016
Sponsor
Maastricht University Medical Center
Collaborators
Novo Nordisk A/S
search

1. Study Identification

Unique Protocol Identification Number
NCT02371239
Brief Title
SIT LESS 2: Effect of Sitting Less on Glucose Regulation in People With Diabetes Mellitus Type 2
Acronym
SIT LESS 2
Official Title
SIT LESS 2: Effect of Sitting Less on Glucose Regulation in People With Diabetes Mellitus Type 2
Study Type
Interventional

2. Study Status

Record Verification Date
March 2016
Overall Recruitment Status
Completed
Study Start Date
February 2015 (undefined)
Primary Completion Date
May 2015 (Actual)
Study Completion Date
May 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Maastricht University Medical Center
Collaborators
Novo Nordisk A/S

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Introduction: Changes in lifestyle are responsible for an important part of the type 2 diabetes epidemic of the last decennia. Current guidelines for physical activity focus mainly on high energy expenditure advising 30 minutes per day moderate to vigorous physical activity (most often physical exercise). Recent studies suggest that sitting has negative metabolic effects independent of the time spent exercising (Duvivier et al. PLOS ONE 2013). Low intensity physical activity (LIPA) -such as walking and standing- has been suggested to be an alternative to decrease the hyperglycaemic effect of sitting. Compared to exercise, LIPA might be a more feasible strategy. But, it remains to be determined whether reducing sitting time by replacing it by LIPA, results in lower 24 hour blood glucose levels and less blood glucose fluctuations (glycaemic variability) in type 2 diabetes patients and whether these effects are independent of the increase in energy expenditure Methods: The study population will involve 19 people with type 2 diabetes (BMI: 25-35 kg/m2) who perform no, or only little, exercise and who are treated with diet only or with oral blood glucose lowering medication. They will perform three regimes of each four days: 1) a sitting regime, 2) an exercise regime and a 3) sit less regime. Daily energy expenditure of the exercise regime will be identical to that of the sit less regime. Sitting, walking and standing will be objectively measured by a 24 hour physical activity monitor. The energy spent during exercise will be standardised and quantified by using a bicycle ergometer; energy intake will be standardised as well. During each regime blood glucose will be measured with a 24 hour continuous glucose sensor.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
Glucose regulation, Glucose, Lipids

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
19 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Sitting regime
Arm Type
Experimental
Arm Description
The subjects will follow the sitting regime during four days. Each day: 14 hours sitting, 1 hour walking and 1 hour standing for daily care and 8 hours sleeping or lying.
Arm Title
Sit Less regime
Arm Type
Experimental
Arm Description
Subjects will follow the sit less regime during four days. Each day will consist of 3 hours walking, 4 hours standing, 9 hours sitting and 8 hours sleeping or lying. The additional 2 hours of walking and 3 hours of standing, compared to the sitting regime, will be done in a minimum of four bouts with a time interval of > 1 hour. The subjects will be instructed to walk on a slow pace. i.e. 2-3 km/h, which is comparable to walking during shopping, walking to the office etc.
Arm Title
Exercise regime
Arm Type
Experimental
Arm Description
Subjects will follow the exercise regime during four days. Each day will consist of 13 hours and 15 minutes sitting, ± 45 minutes supervised cycling on an ergometer, 1 hour walking and 1 hour standing for daily care and 8 hours sleeping or lying.
Intervention Type
Behavioral
Intervention Name(s)
Physical activity intervention
Primary Outcome Measure Information:
Title
Mean 24 hour glucose concentration
Time Frame
during the last 24 hours of an activity regime
Secondary Outcome Measure Information:
Title
Total duration (minutes) of hyperglycaemia (glucose > 10 mmol/L)
Time Frame
during the last 24 hours of an activity regime
Title
Mean 24 hour glucose concentration
Time Frame
during a whole activity regime
Title
Total duration of hyperglycaemia (glucose > 10 mmol/L)
Time Frame
during a whole activity regime
Title
Area under the curve of hyperglycaemia (glucose > 10 mmol/L)
Time Frame
during the last 24 hours of an activity regime
Title
Glucose variability measured as SD divided by mean
Time Frame
the last 24 hours of each regime
Title
Total duration of hypoglycaemia (glucose ≤ 3.9 mmol/L)
Time Frame
during a whole activity regime
Title
Fasting total cholesterol
Time Frame
one day after each activity regime
Title
Non-HDL cholesterol
Time Frame
one day after each activity regime
Title
HDL cholesterol
Time Frame
one day after each activity regime
Title
LDL cholesterol
Time Frame
one day after each activity regime
Title
Triglycerides
Time Frame
one day after each activity regime
Title
Apolipoprotein B
Time Frame
one day after each activity regime
Title
Apolipoprotein A
Time Frame
one day after each activity regime
Title
Free fatty acids
Time Frame
one day after each activity regime
Title
Fasting glucose
Time Frame
one day after each activity regime
Title
Fasting insulin
Time Frame
one day after each activity regime
Title
Fasting C-peptide
Time Frame
one day after each activity regime
Title
Fasting CRP
Time Frame
one day after each activity regime
Title
Fasting IL-6
Time Frame
one day after each activity regime
Title
Fasting IL-1
Time Frame
one day after each activity regime
Title
Homeostatic model assessment 2 (HOMA2)
Description
to assess insulin sensitivity
Time Frame
one day after each activity regime

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Signed informed consent Men and women: 40-75 years old Diabetes mellitus type 2, developed after the age of 40 years old Treatment with diet or oral blood glucose lowering medication (metformin and/or SU-derivatives and/or DPP-IV inhibitors) HbA1c: < 10% BMI: 25.0 - 35.0 kg/m2 Maximum 2.5 hours of MVPA per week (during last 3 months) Internet availability on a daily basis Exclusion Criteria: Pregnancy or intention of becoming pregnant Alcohol use: > 2 units per day (during the last 3 months) Experimental drug use (during the last 3 months) Use of insulin, corticosteroids, vitamin K antagonists and immunosuppressive drugs in the last 3 months Triglyceride level > 10.0 mmol/L Fasting plasma glucose level > 10 mmol/L Heart failure NYHA 3 or higher Angina pectoris or signs of cardiac ischemia during exercise testing COPD Gold 3 or higher Glomerular filtration rate (GFR) < 30 ml/min Diagnosis of active cancer (not cancer in the past that is cured) Diabetes mellitus type 1 Intermittent claudication with a walking distance < 500 meter Not able to cycle for ± 45 minutes, as judged from the incremental exhaustive exercise bicycle-ergometer test at Visit 1 Based on historical information not able to walk for 3 hours per day and stand for 4 hours per day Mental or physical disability which makes physical activity not possible Participation in a clinical trial with medication use (in the last 3 months) Severe loss of vision Active foot ulcer or venous leg ulcer
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nicolaas C Schaper, MD PhD
Organizational Affiliation
Maastricht University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Human Movement Science, Maastricht University
City
Maastricht
State/Province
Limburg
ZIP/Postal Code
6200 MD
Country
Netherlands

12. IPD Sharing Statement

Citations:
PubMed Identifier
23418444
Citation
Duvivier BM, Schaper NC, Bremers MA, van Crombrugge G, Menheere PP, Kars M, Savelberg HH. Minimal intensity physical activity (standing and walking) of longer duration improves insulin action and plasma lipids more than shorter periods of moderate to vigorous exercise (cycling) in sedentary subjects when energy expenditure is comparable. PLoS One. 2013;8(2):e55542. doi: 10.1371/journal.pone.0055542. Epub 2013 Feb 13. Erratum In: PLoS One. 2014;9(8):e105135.
Results Reference
background
PubMed Identifier
27904925
Citation
Duvivier BM, Schaper NC, Hesselink MK, van Kan L, Stienen N, Winkens B, Koster A, Savelberg HH. Breaking sitting with light activities vs structured exercise: a randomised crossover study demonstrating benefits for glycaemic control and insulin sensitivity in type 2 diabetes. Diabetologia. 2017 Mar;60(3):490-498. doi: 10.1007/s00125-016-4161-7. Epub 2016 Nov 30.
Results Reference
derived
Links:
URL
http://www.plosone.org/article/metrics/info%3Adoi%2F10.1371%2Fjournal.pone.0055542
Description
Related Info

Learn more about this trial

SIT LESS 2: Effect of Sitting Less on Glucose Regulation in People With Diabetes Mellitus Type 2

We'll reach out to this number within 24 hrs